TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

1997 • 5,058 citations

Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

1999 • 2,494 citations

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 • 2,215 citations

A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA

2013 • 2,176 citations

The Receptor for the Cytotoxic Ligand TRAIL

1997 • 1,755 citations

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

1997 • 1,694 citations

An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL

1997 • 1,506 citations

Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL

1998 • 1,177 citations

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL

1997 • 1,119 citations

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

2000 • 847 citations

The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain

1997 • 829 citations

Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells

1998 • 671 citations

A novel receptor for Apo2L/TRAIL contains a truncated death domain

1997 • 650 citations

Cells: a laboratory manual

1998 • 635 citations

Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family

1997 • 634 citations

Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL

1997 • 566 citations

Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

1999 • 557 citations

TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL

1997 • 331 citations

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study

2000 • 317 citations

Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies

1999 • 241 citations

INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA

1989 • 198 citations

TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells

1999 • 158 citations

Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL.

1998 • 142 citations

Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies

1997 • 124 citations

False human hematopoietic cell lines: cross-contaminations and misinterpretations

1999 • 122 citations

Cutting Edge: Lymphocyte Inhibitor of TRAIL (TNF-Related Apoptosis-Inducing Ligand): A New Receptor Protecting Lymphocytes from the Death Ligand TRAIL

1998 • 104 citations

Culture and biochemical analysis of cells

1998 • 57 citations

Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantation

1996 • 47 citations

Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades

1999 • 30 citations

BCR‐ABL‐positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions

1996 • 9 citations